Analysis of very elderly (≥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome.
about
Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potentialDiffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States.Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma.Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapyFactors that influence treatment decision-making in elderly DLBCL patients: a case vignette studyComparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma.The Impact of Age and Sex in DLBCL: Systems Biology Analyses Identify Distinct Molecular Changes and Signaling Networks.Efficacy and tolerability of anthracycline-based therapy in elderly patients with diffuse large B-cell lymphoma.International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancerComparison of Three Chemotherapy Regimens in Elderly Patients with Diffuse Large B Cell Lymphoma: Experience at a Single National Reference Center in Mexico.Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States.Impact of comorbidities on the treatment of non-Hodgkin's lymphoma: a systematic review.Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma.High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma.Prognostic significance of geriatric assessment in combination with laboratory parameters in elderly patients with aggressive non-Hodgkin lymphoma.Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi.Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma.Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma.Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions.Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).
P2860
Q26747753-E0B24015-3FAA-47CB-9A99-64D98A7BC227Q30235296-2FC36DB7-DF30-43DE-99F6-EBA379BCC07CQ34640973-9E9A0264-4A0F-4ED6-8934-35AC2198E260Q35581741-8319B777-559A-4BA6-9BBB-F78C7C3972CDQ35637806-437E76FB-174A-4CF1-83D2-A17EB43B0964Q35784338-BBA32EA2-4126-4BBD-93F2-948F4C497077Q35807965-9232477B-CABC-499A-938E-5FE6B762AA9AQ36160955-2463CD60-96AA-4C73-AED1-EFF12AB57C32Q36365020-87B192E2-D7C2-40CB-873F-0F8DAF7802B5Q36908665-A9F1E6B7-E9C6-48AF-94C3-48E92B87F15DQ36925135-7A7C470A-6018-4C59-86DE-F8F07D8EEBCBQ37120684-8027D5D0-E2BA-439F-9639-DCFC2A65DCA6Q37361547-49FC59DF-4ECE-4305-84E2-974221BBB783Q38378318-3337B603-C6AA-4E57-BB65-B0B50A2B60FBQ38700745-2779B8DB-8BEF-42BE-B96F-819930EB6D92Q40163155-18244417-CF63-4C98-866F-B979D5135F40Q41618393-33265DDF-D4E0-4F0F-9E2D-59E9177FC5D1Q43529478-2DAE07C8-7783-472B-B301-665EAEFB5C18Q43782234-5D9F1D90-F648-46CB-8090-875E6890F0DFQ44482782-D90792F9-0126-4051-9437-94C97118C666Q44950915-30E5ED37-2F4C-428B-980E-6A40DDB1C6A5Q47565688-8A8909FB-A3D4-433A-B4F0-F8793B74486DQ48266876-463780BD-1E97-4A7D-AA4F-0A1461A294CBQ52577099-35EB5A37-A851-47E4-955B-F60F856F14F1
P2860
Analysis of very elderly (≥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Analysis of very elderly (≥80 ...... and co-morbidities on outcome.
@en
Analysis of very elderly
@nl
type
label
Analysis of very elderly (≥80 ...... and co-morbidities on outcome.
@en
Analysis of very elderly
@nl
prefLabel
Analysis of very elderly (≥80 ...... and co-morbidities on outcome.
@en
Analysis of very elderly
@nl
P2093
P2860
P50
P1476
Analysis of very elderly (≥80 ...... and co-morbidities on outcome
@en
P2093
Annette Larsen
Britt Hanson
Chadi Nabhan
Erika Ramsdale
Irene Helenowski
Josephine Feliciano
June McKoy
Scott Smith
Sonali M Smith
Stephanie Gregory
P2860
P304
P356
10.1111/J.1365-2141.2011.08934.X
P407
P577
2011-11-16T00:00:00Z